Buzz Stocks: Microsoft, Vascular Biogenics, Celladon Corp

Today's stocks to watch in the news include Microsoft Corporation (NASDAQ:MSFT), Vascular Biogenics Ltd (NASDAQ:VBLT), and Celladon Corp (NASDAQ:CLDN)

Jun 1, 2015 at 9:40 AM
facebook twitter linkedin

U.S. stocks kicked off the week on a high note, with the major indexes sitting in the black. In company news, today's stocks to watch include software giant Microsoft Corporation (NASDAQ:MSFT), as well as drugmakers Vascular Biogenics Ltd (NASDAQ:VBLT) and Celladon Corp (NASDAQ:CLDN)

  • MSFT announced its Windows 10 operating system will be available globally on Wednesday, July 29. Users of Windows 7 and 8.1 can upgrade to the new version for free. In early trading, Microsoft Corporation shares are 0.7% higher at $47.17, but have struggled longer term -- up less than 2% year-to-date. As such, options traders have been buying to open puts over calls at an accelerated clip in recent months. MSFT's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.73 ranks just 12 percentage points from a 12-month peak. Echoing this, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.79 sits in the put-skewed 70th percentile of its annual range.

  • VBLT is 7.3% higher at $8.64, thanks to encouraging trial results from its brain tumor drug, VB-111. From a relative-strength perspective, Vascular Biogenics Ltd has outperformed the broader S&P 500 Index (SPX) by 117 percentage points over the last 20 sessions, and is more than 47% higher year-to-date. Not surprisingly, all three analysts tracking the stock rate it a "strong buy," and VBLT's consensus 12-month price target of $13 stands in territory not charted since a mid-February bear gap.

  • Finally, CLDN is looking for a strategic partnership or acquisition, following the disappointing performance of its heart drug in a mid-stage trial. The company also named Chief Financial Officer Paul Cleveland as its new CEO, after Krisztina Zsebo resigned from the post. These developments have the equity sitting 12.1% higher at $2.59. Longer term, though, Celladon Corp has performed terribly, shedding 86.7% of its value in 2015. On the sentiment front, each of the four brokerage firms following CLDN consider it a "hold," while its average 12-month price target of $2.33 is roughly in line with current trading levels.

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1